7 documents found, page 1 of 1

Sequential T790M mutation testing and changes in the therapeutic approach after...

The EGFR mutation is identified in 10-50% of patients with non-small cell lung cancer (NSCLC). After first-line therapy, with 1st or 2nd line tyrosinacinase (TKI) inhibitors, in patients with NSCLC and a sensitizing EGFR mutation the most frequent mechanism of resistance is the acquisition of a T790M mutation, in 50-70%. We present the clinical case of a woman with NSCLC, cT2bN1M1b, stage IV with cerebral and a...

Lung Cancer Screening in Portugal: A PULMONALE Pilot Project

N/a.; N/a.

Osimertinib-induced cutaneous vasculitis: A case report and review of the liter...

A 77-year-old patient with a history of stage IVa (cT4N3M1a) lung adenocarcinoma, treated with osimertinib 80 mg/day, developed palpable purpura nine days after starting therapy. Skin biopsy revealed leukocytoclastic vasculitis. A complete clinical and lab workup for systemic involvement was unremarkable. The patient suspended osimertinib and started on methylprednisone 1mg/Kg/day. Skin lesions gradually improv...

When the stenting in the approach to superior vena cava syndrome allows radical...

Superior vena cava syndrome is an oncological emergency. It is life-threatening in 15% of the cases. When it is severe and the presentation form of malignancy, a multidisciplinary diagnostic and therapeutic approach is challenging and urgent. We present the case of a patient with no previous cancer that came to the emergency department due to superior vena cava syndrome. He had oedema of the face, cervical regi...

O futuro na doença oligometastática

Pesquisa de mutação T790M sequencial e alteração da abordagem terapêutica após ...

A mutação do EGFR é identificada em 10 -50% dos doentes com cancro do pulmão de não pequenas células (CPNPC). Após terapêutica de primeira linha com inibidores da tirosinacinase (TKI) de 1.ª ou 2.ª linha, em doentes com CPNPC e mutação sensibilizadora do EGFR, o mecanismo de resistência mais frequente é a aquisição de mutação T790M, em 50 -70%. Apresenta -se o caso clínico de uma mulher com CPNPC, cT2bN1M1b, es...

Spinal Cord Compression by Testicular Germ Cell Tumor: Case Report

Malignant spinal cord compression occurs in 2.5% - 5% cancer patients. Early diagnosis and therapeutic intervention are critical for paincontrol and improvement of any neurological deficit. Treatment should be directed to the underlying disease together with appropriatesymptom management.The case of a man with tetraparesis of 24 hours duration is presented. He had surgery five days earlier because of a testicul...